Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David W Dodick

Showing results (161-170 of 365) with videos related to

Pageof 37
Sort By:
Pain and Therapy|October 7, 2020
The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic MigraineStephen D Silberstein, Hans-Christoph Diener, David W Dodick, et al.
Headache|September 2, 2017
Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive MedicinesJoshua M Cohen, David W Dodick, Ronghua Yang, et al.
Headache|April 8, 2017
Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal OutcomesAndrew M Blumenfeld, Stephen D Silberstein, David W Dodick, et al.
Cephalalgia : an International Journal of Headache|March 7, 2020
Acute treatment patterns in patients with migraine newly initiating a triptanRichard B Lipton, Steven C Marcus, Anand R Shewale, et al.
Pain and Therapy|October 7, 2020
Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT AnalysisHans-Christoph Diener, David W Dodick, Richard B Lipton, et al.
Headache|May 22, 2018
Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled TrialDavid W Dodick, Stewart J Tepper, Deborah I Friedman, et al.
Headache|June 26, 2020
Open-Label, Multi-Dose, Pilot Safety Study of Injection of OnabotulinumtoxinA Toward the Otic Ganglion for the Treatment of Intractable Chronic Cluster HeadacheJoan Crespi, Daniel Bratbak, David W Dodick, et al.
Cephalalgia : an International Journal of Headache|June 26, 2019
Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trialDavid W Dodick, Richard B Lipton, Stephen Silberstein, et al.
Headache|May 11, 2019
Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter TrialDavid Yarnitsky, David W Dodick, Brian M Grosberg, et al.
The Lancet. Neurology|August 16, 2014
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled studyDavid W Dodick, Peter J Goadsby, Egilius L H Spierings, et al.
Pageof 37

Showing results (161-170 of 365) with videos related to

Sort By:
Pageof 37
Pain and Therapy|October 7, 2020
The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic MigraineStephen D Silberstein, Hans-Christoph Diener, David W Dodick, et al.
Headache|September 2, 2017
Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive MedicinesJoshua M Cohen, David W Dodick, Ronghua Yang, et al.
Headache|April 8, 2017
Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal OutcomesAndrew M Blumenfeld, Stephen D Silberstein, David W Dodick, et al.
Cephalalgia : an International Journal of Headache|March 7, 2020
Acute treatment patterns in patients with migraine newly initiating a triptanRichard B Lipton, Steven C Marcus, Anand R Shewale, et al.
Pain and Therapy|October 7, 2020
Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT AnalysisHans-Christoph Diener, David W Dodick, Richard B Lipton, et al.
Headache|May 22, 2018
Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled TrialDavid W Dodick, Stewart J Tepper, Deborah I Friedman, et al.
Headache|June 26, 2020
Open-Label, Multi-Dose, Pilot Safety Study of Injection of OnabotulinumtoxinA Toward the Otic Ganglion for the Treatment of Intractable Chronic Cluster HeadacheJoan Crespi, Daniel Bratbak, David W Dodick, et al.
Cephalalgia : an International Journal of Headache|June 26, 2019
Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trialDavid W Dodick, Richard B Lipton, Stephen Silberstein, et al.
Headache|May 11, 2019
Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter TrialDavid Yarnitsky, David W Dodick, Brian M Grosberg, et al.
The Lancet. Neurology|August 16, 2014
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled studyDavid W Dodick, Peter J Goadsby, Egilius L H Spierings, et al.
Pageof 37